MedTrace Logo

Unintentional Weight Loss and Cancer: A Prospective Trial of Patient-centered Weight Tracking Combin

NCT05481697 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2026-02-19

No results posted yet for this study

Summary

Unintentional weight loss (UWL) is commonly associated with a wide variety of diseases and there is still no valid diagnostic pathway for evaluating UWL. When detecting UWL coupled with GRAIL Galleri testing, (an investigational pan-cancer early detection test), it is thought that there is a greater positive predictive value in detecting malignancies. This study aims to test the potential synergistic effects of UWL detection and GRAIL usage to detect malignancy at an even earlier rate. UWL will be measured using weekly weight tracking.

Conditions

  • Unintended Weight Loss

Interventions

DIAGNOSTIC_TEST

GRAIL Galleri

A blood test that aims to detect cancers earlier by looking for abnormal DNA shed from cancer cells into the blood.

Sponsors & Collaborators

  • University Hospitals Seidman Cancer Center

    collaborator OTHER

  • Case Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Jordan M Winter, MD · University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-05
Primary Completion
2027-01-01
Completion
2027-01-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05481697 on ClinicalTrials.gov